Gilead starts testing inhaled form of remdesivir
Gilead Sciences Inc. announced on Wednesday that it started the Phase 1a clinical trial of “investigational, inhaled solution of remdesivir in healthy volunteers.”
Around 60 people aged 18-45 will be participating in the “randomized, placebo-controlled trial” in the United States, the company’s Chief Medical Officer Merdad Parsey said in a statement. The main aim of the trial is to “form the basis for further clinical study of the inhaled drug,” particularly in patients not requiring hospitalization, he added.
“Additional clinical trials evaluating remdesivir in combination with anti-inflammatory medicines, in vulnerable patient populations and in outpatient settings are ongoing or planned to initiate in the near future,” Parsey pointed out.
Get involved!
Comments